Rar Alpha/Rxr Synergism Potentiates Retinoid Responsiveness In Cutaneous T-Cell Lymphoma Cell Lines

Retinoids, natural and synthetic derivatives of vitamin A, induce cellular changes by activating nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR). Although the ability of retinoids to govern gene expression is exploited clinically for cancer therapeutics, the full benefit of retinoid-based strategies is unrealized due to detrimental side effects. Delineating the receptors that prompt cellular outcomes is critical to advancing retinoid-based approaches. Here, we identify the receptors that evoke multiple responses in cutaneous T-cell lymphoma (CTCL). The data demonstrate that RAR drives integrin 7-dependent adhesion and CCR9-mediated chemotaxis in CTCL cells. Of note, concomitant activation of RAR and RXR nuclear receptors yielded synergistic increases in adhesion and migration at concentrations where single agents were ineffective. As the established paradigm of retinoid action in CTCL is apoptosis and growth arrest, the role of RAR/RXR in these events was studied. As with adhesion and migration, RAR/RXR synergism prompted apoptosis and dampened CTCL cell proliferation. Strikingly, RAR/RXR synergism induced responses from CTCL cell lines previously reported to be unresponsive to retinoids. These data provide a novel framework that may further refine a proven CTCL therapy.